Bimatoprost implant



Intracameral bimatoprost 10-μg implant is a valuable addition for treating patients with ocular hypertension and glaucoma.



Tradename Durysta



The benefits of the sustained-release prostaglandin significantly outweigh any risk associated with its administration.



The recipients of the bimatoprost implant, are able to eliminate or reduce their topical medications.



The surgical system decreases IOP in patients with POAG​.



The bimatoprost implant has the ability to reduce ocular surface toxicity from topical drops 



The implantation procedure is done with the eye topically anesthetized and under aseptic conditions. 



The implant into its targeted location in the inferior angle.



IOP-lowering benefit can last from 4 months to 2 years or more.



Leave a Reply

Your email address will not be published. Required fields are marked *